File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.neurobiolaging.2006.05.005
- Scopus: eid_2-s2.0-34247172100
- PMID: 16806588
- WOS: WOS:000246253300008
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Neuroprotective effect of Coenzyme Q10 on ischemic hemisphere in aged mice with mutations in the amyloid precursor protein
Title | Neuroprotective effect of Coenzyme Q10 on ischemic hemisphere in aged mice with mutations in the amyloid precursor protein |
---|---|
Authors | |
Keywords | Alzheimer's disease Antioxidant APP/PS1 double transgenic mice Cerebral infarction Stroke |
Issue Date | 2007 |
Publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/neuaging |
Citation | Neurobiology Of Aging, 2007, v. 28 n. 6, p. 877-882 How to Cite? |
Abstract | This study was designed to test whether Coenzyme Q10 (CoQ10) supplementation has neuroprotective effect in aged, double-transgenic amyloid precursor protein (APP)/presenilin 1 (PS1), single transgenic APP and PS1 mice exposed to ischemic injury of the brain. Forty-eight mice (12 each of APP/PS1, APP, PS1 and wild-type) were studied. Half of each genotype groups (n = 6 per group) was treated with CoQ10 (1200 mg/kg/day) after ischemic injury and the other half with placebo. Magnetic resonance (MR) images were used to measure the volume of induced infarction (IFV), as well as the volume of the hemispheres and hippocampi. Significantly greater volumes of infarction and lesser volumes of hemisphere/hippocampus on the ischemic side were observed in APP/PS1 and APP mice than in PS1 and wild-type mice. This is consistent with amplification of the effect of ischemia in APP carriers. After 28 days of CoQ10 treatment, APP/PS1 or APP mutations have smaller infarct volumes, while the volumes of hemisphere and hippocampus on the infarcted side were larger than those treated with placebo. No differences between CoQ10- and placebo-treated groups in volumes of infarct, hemisphere and hippocampus were observed in PS1 and wild-type mice. We conclude that CoQ10 has a protective effect on the brain from infarction and atrophy induced by ischemic injury in aged and susceptible transgenic mice. © 2006 Elsevier Inc. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/155367 |
ISSN | 2023 Impact Factor: 3.7 2023 SCImago Journal Rankings: 1.488 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, G | en_US |
dc.contributor.author | Zou, L | en_US |
dc.contributor.author | Jack Jr, CR | en_US |
dc.contributor.author | Yang, Y | en_US |
dc.contributor.author | Yang, ES | en_US |
dc.date.accessioned | 2012-08-08T08:33:06Z | - |
dc.date.available | 2012-08-08T08:33:06Z | - |
dc.date.issued | 2007 | en_US |
dc.identifier.citation | Neurobiology Of Aging, 2007, v. 28 n. 6, p. 877-882 | en_US |
dc.identifier.issn | 0197-4580 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/155367 | - |
dc.description.abstract | This study was designed to test whether Coenzyme Q10 (CoQ10) supplementation has neuroprotective effect in aged, double-transgenic amyloid precursor protein (APP)/presenilin 1 (PS1), single transgenic APP and PS1 mice exposed to ischemic injury of the brain. Forty-eight mice (12 each of APP/PS1, APP, PS1 and wild-type) were studied. Half of each genotype groups (n = 6 per group) was treated with CoQ10 (1200 mg/kg/day) after ischemic injury and the other half with placebo. Magnetic resonance (MR) images were used to measure the volume of induced infarction (IFV), as well as the volume of the hemispheres and hippocampi. Significantly greater volumes of infarction and lesser volumes of hemisphere/hippocampus on the ischemic side were observed in APP/PS1 and APP mice than in PS1 and wild-type mice. This is consistent with amplification of the effect of ischemia in APP carriers. After 28 days of CoQ10 treatment, APP/PS1 or APP mutations have smaller infarct volumes, while the volumes of hemisphere and hippocampus on the infarcted side were larger than those treated with placebo. No differences between CoQ10- and placebo-treated groups in volumes of infarct, hemisphere and hippocampus were observed in PS1 and wild-type mice. We conclude that CoQ10 has a protective effect on the brain from infarction and atrophy induced by ischemic injury in aged and susceptible transgenic mice. © 2006 Elsevier Inc. All rights reserved. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/neuaging | en_US |
dc.relation.ispartof | Neurobiology of Aging | en_US |
dc.subject | Alzheimer's disease | - |
dc.subject | Antioxidant | - |
dc.subject | APP/PS1 double transgenic mice | - |
dc.subject | Cerebral infarction | - |
dc.subject | Stroke | - |
dc.subject.mesh | Aging | en_US |
dc.subject.mesh | Amyloid Beta-Protein Precursor - Genetics | en_US |
dc.subject.mesh | Analysis Of Variance | en_US |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Coenzymes | en_US |
dc.subject.mesh | Functional Laterality | en_US |
dc.subject.mesh | Hippocampus - Drug Effects - Pathology | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Ischemia - Pathology - Prevention & Control | en_US |
dc.subject.mesh | Magnetic Resonance Imaging - Methods | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Mice | en_US |
dc.subject.mesh | Mice, Inbred C57bl | en_US |
dc.subject.mesh | Mice, Transgenic | en_US |
dc.subject.mesh | Mutation | en_US |
dc.subject.mesh | Neuroprotective Agents - Therapeutic Use | en_US |
dc.subject.mesh | Presenilin-1 - Genetics | en_US |
dc.subject.mesh | Ubiquinone - Analogs & Derivatives - Therapeutic Use | en_US |
dc.title | Neuroprotective effect of Coenzyme Q10 on ischemic hemisphere in aged mice with mutations in the amyloid precursor protein | en_US |
dc.type | Article | en_US |
dc.identifier.email | Yang, ES:esyang@hkueee.hku.hk | en_US |
dc.identifier.authority | Yang, ES=rp00199 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/j.neurobiolaging.2006.05.005 | en_US |
dc.identifier.pmid | 16806588 | - |
dc.identifier.scopus | eid_2-s2.0-34247172100 | en_US |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-34247172100&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 28 | en_US |
dc.identifier.issue | 6 | en_US |
dc.identifier.spage | 877 | en_US |
dc.identifier.epage | 882 | en_US |
dc.identifier.isi | WOS:000246253300008 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Li, G=35767974200 | en_US |
dc.identifier.scopusauthorid | Zou, L=23391539300 | en_US |
dc.identifier.scopusauthorid | Jack Jr, CR=18033457700 | en_US |
dc.identifier.scopusauthorid | Yang, Y=7409387192 | en_US |
dc.identifier.scopusauthorid | Yang, ES=7202021229 | en_US |
dc.identifier.issnl | 0197-4580 | - |